Neuroprotective effect of latanoprost on rat retinal ganglion cells

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 244, Issue 8, 2006, Pages 1003-1009

  Kudo, Hideyo ^a   Nakazawa, Toru ^a   Shimura, Masahiko ^a,b   Takahashi, Hidetoshi ^a   Fuse, Nobuo ^a   Kashiwagi, Kenji ^c   Tamai, Makoto ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NTT East Tohoku Hospital   (Japan)

^c UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Axotomy; Glaucoma; Latanoprost; N Methyl D aspartic acid; Neuroprotection; Retinal ganglion ganglion cell

Indexed keywords

FLUOROGOLD; LATANOPROST; N METHYL DEXTRO ASPARTIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL COUNT; CELL LABELING; CELL SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; IN VIVO STUDY; MALE; NERVE FIBER TRANSECTION; NEUROPROTECTION; NONHUMAN; OPTIC NERVE; OPTIC NERVE INJURY; PRIORITY JOURNAL; RAT; RETINA GANGLION CELL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ANIMALS; ANTIHYPERTENSIVE AGENTS; AXOTOMY; CELL COUNT; CELL SURVIVAL; INJECTIONS; MALE; N-METHYLASPARTATE; NEUROPROTECTIVE AGENTS; PROSTAGLANDINS F, SYNTHETIC; RATS; RATS, SPRAGUE-DAWLEY; RETINAL GANGLION CELLS; VITREOUS BODY;

EID: 33746880248     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-005-0215-0     Document Type: Article

References (38)

1. Abramovitz M, Boie Y, Nguyen T, Rushmore TH, Bayne MA, Metters KM, Slipetz DM, Grygorczyk R (1994) Cloning and expression of a cDNA for the human prostanoid FP receptor. J Biol Chem 269:2632-2636
2. Ahmed F, Brown KM, Stephan DA, Morrison JC, Johnson EC, Tomarev SI (2004) Microarray analysis of changes in mRNA levels in the rat retina after experimental elevation of intraocular pressure. Invest Ophthalmol Vis Sci 45:1247-1258
3. Ahmed F, Torrado M, Johnson E, Morrison J, Tomarev SI (2001) Changes in mRNA levels of the Myoc/Tigr gene in the rat eye after experimental elevation of intraocular pressure or optic nerve transection. Invest Ophthalmol Vis Sci 42:3165-3172
4. Akiyama H, Nakazawa T, Shimura M, Tomita H, Tamai M (2002) Presence of mitogen-activated protein kinase in retinal Muller cells and its neuroprotective effect ischemia-reperfusion injury. Neuroreport 13:2103-2107
5. Alm A, Stjernschantz J (1995) Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology 102:1743-1752
6. Ansari HR, Kaddour-Djebbar I, Abdel-Latif AA (2004) Effects of prostaglandin F2alpha, latanoprost and carbachol on phosphoinositide turnover, MAP kinases, myosin light chain phosphorylation and contraction and functional existence and expression of FP receptors in bovine iris sphincter. Exp Eye Res 78:285-296
7. Araie M, Takase M, Sakai Y, Ishii Y, Yokoyama Y, Kitagawa M (1982) Beta-adrenergic blockers: Ocular penetration and binding to the uveal pigment. Jpn J Ophthalmol 26:248-263
8. Bautista RD (1999) Glaucomatous neurodegeneration and the concept of neuroprotection. Int Ophthalmol Clin 39:57-70
9. Chen CC, Koda RT, Shackleton M (1988) The ocular distribution of bunolol in the eyes of albino and pigmented rabbits. J Ocul Pharmacol 4:37-42
10. Drago F, Valzelli S, Emmi I, Marino A, Scalia CC, Marino V (2001) Latanoprost exerts neuroprotective activity in vitro and in vivo. Exp Eye Res 72:479-486
11. Endo S, Tomita H, Ishiguro S, Tamai M (2002) Effect of betaxolol on aspartate aminotransferase activity in hypoxic rat retina in vitro. Jpn J Pharmacol 90:121-124
12. Fujio N, Kusumoto N, Odomi M (1994) Ocular distribution of carteolol after single and repeated ocular instillation in pigmented rabbits. Acta Ophthalmol (Copenh) 72:688-693
13. Goto W, Ota T, Morikawa N, Otori Y, Hara H, Kawazu K, Miyawaki N, Tano Y (2002) Protective effects of timolol against the neuronal damage induced by glutamate and ischemia in the rat retina. Brain Res 958:10-19
14. Hejkal TW, Camras CB (1999) Prostaglandin analogs in the treatment of glaucoma. Semin Ophthalmol 14:114-123
15. Ishii K, Tomidokoro A, Nagahara M, Tamaki Y, Kanno M, Fukaya Y, Araie M (2001) Effects of topical latanoprost on optic nerve head circulation in rabbits, monkeys, and humans. Invest Ophthalmol Vis Sci 42:2957-2963
16. Kashiwagi K, Iizuka Y, Tsukahara S (2002) Neuroprotective effects of nipradilol on purified cultured retinal ganglion cells. J Glaucoma 11:231-238
17. Kashiwagi K, Kanai N, Tsuchida T, Suzuki M, Iizuka Y, Tanaka Y, Tsukahara S (2002) Comparison between isopropyl unoprostone and latanoprost by prostaglandin E(2)induction, affinity to prostaglandin transporter, and intraocular metabolism. Exp Eye Res 74:41-49
18. Kaushik S, Pandav SS, Ram J (2003) Neuroprotection in glaucoma. J Postgrad Med 49:90-95
19. Koeberle PD, Ball AK (1998) Effects of GDNF on retinal ganglion cell survival following axotomy. Vision Res 38:1505-1515
20. Kunapuli P, Lawson JA, Rokach JA, Meinkoth JL, FitzGerald GA (1998) Prostaglandin F2alpha (PGF2alpha) and the isoprostane, 8, 12-iso-isoprostane F2alpha-III, induce cardiomyocyte hypertrophy. Differential activation of downstream signaling pathways. J Biol Chem 273:22442-22452
21. Levin LA (2003) Retinal ganglion cells and neuroprotection for glaucoma. Surv Ophthalmol 48:S21-S24
22. Matsuo T, Cynader MS (1992) Localisation of prostaglandin F2 alpha and E2 binding sites in the human eye. Br J Ophthalmol 76:210-213
23. McCullough L, Wu L, Haughey N, Liang X, Hand T, Wang Q, Breyer RM, Andreasson K (2004) Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J Neurosci 24:257-268
24. Melamed S (2002) Neuroprotective properties of a synthetic docosanoid, unoprostone isopropyl: Clinical benefits in the treatment of glaucoma. Drugs Exp Clin Res 28:63-73
25. Mizuno K, Koide T, Saito N, Fujii M, Nagahara M, Tomidokoro A, Tamaki Y, Araie M (2002) Topical nipradilol: Effects on optic nerve head circulation in humans and periocular distribution in monkeys. Invest Ophthalmol Vis Sci 43:3243-3250
26. Mizuno K, Koide T, Yoshimura M, Araie M (2001) Neuroprotective effect and intraocular penetration of nipradilol, a beta-blocker with nitric oxide donative action. Invest Ophthalmol Vis Sci 42:688-694
27. Nakazawa T, Nakano I, Sato M, Nakamura T, Tamai M, Mori N (2002) Comparative expression profiles of Trk receptors and Shc-related phosphotyrosine adapters during retinal development: Potential roles of N-Shc/ShcC in brain-derived neurotrophic factor signal transduction and modulation. J Neurosci Res 68:668-680
28. Nakazawa T, Shimura M, Tomita H, Akiyama H, Yoshioka Y, Kudou H, Tamai M (2003) Intrinsic activation of PI3K/Akt signaling pathway and its neuroprotective effect against retinal injury. Curr Eye Res 26:55-63
29. Nakazawa T, Tamai M, Mori N (2002) Brain-derived neurotrophic factor prevents axotomized retinal ganglion cell death through MAPK and PI3K signaling pathways. Invest Ophthalmol Vis Sci 43:3319-3326
30. Nakazawa T, Tomita H, Yamaguchi K, Sato Y, Shimura M, Kuwahara S, Tamai M (2002) Neuroprotective effect of nipradilol on axotomized rat retinal ganglion cells. Curr Eye Res 24:114-122
31. Osborne NN, Cazevieille C, Carvalho AL, Larsen AK, DeSantis L (1997) In vivo and in vitro experiments show that betaxolol is a retinal neuroprotective agent. Brain Res 751:113-123
32. Quigley HA (1996) Number of people with glaucoma worldwide. Br J Ophthalmol 80:389-393
33. Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP (2004) Global data on visual impairment in the year 2002. Bull World Health Org 82:844-851
34. Schlotzer-Schrehardt U, Zenkel M, Nusing RM (2002) Expression and localization of FP and EP prostanoid receptor subtypes in human ocular tissues. Invest Ophthalmol Vis Sci 43:1475-1487
35. Vorwerk CK, Hyman BT, Miller JW, Husain D, Zurakowski D, Huang PL, Fishman MC, Dreyer EB (1997) The role of neuronal and endothelial nitric oxide synthase in retinal excitotoxicity. Invest Ophthalmol Vis Sci 38:2038-2044
36. Wheeler LA, Gil DW, WoldeMussie E (2001) Role of alpha-2 adrenergic receptors in neuroprotection and glaucoma. Surv Ophthalmol 45:S290-294; discussion S295-S296
37. Wheeler LA, Lai R, Woldemussie E (1999) From the lab to the clinic: activation of an alpha-2 agonist pathway is neuroprotective in models of retinal and optic nerve injury. Eur J Ophthalmol 9:S17-S21
38. Yucel YH, Zhang Q, Weinreb RN, Kaufman PL, Gupta N (2003) Effects of retinal ganglion cell loss on magno-, parvo-, koniocellular pathways in the lateral geniculate nucleus and visual cortex in glaucoma. Prog Retin Eye Res 22:465-481